Literature DB >> 7525108

Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors.

B A French1, W Mazur, R S Geske, R Bolli.   

Abstract

BACKGROUND: Efficient methods of introducing genes into myocardial cells must be developed before local somatic cell gene therapy can be implemented against myocardial disease. Although adenoviral (Ad5) vectors have been used to target rodent hearts and plasmid DNA has been directly injected into the myocardium of rats and dogs, the amounts of recombinant protein produced by these procedures have not been reported, and adenoviral vectors have not been used in large mammalian hearts. METHODS AND
RESULTS: Replication-deficient recombinant adenoviral vectors carrying either the luciferase or lacZ reporter genes were injected directly into the ventricular myocardium of adult domestic swine for evaluation of reporter gene expression. This procedure did not affect regional myocardial function as assessed by systolic wall thickening using ultrasonic crystals. Luciferase activity was detected 3 days after injection, increased markedly at 7 days, and then declined progressively at 14 and 21 days. Luciferase production was comparable in the right and left ventricular walls and increased with increasing amounts of virus, reaching 61 +/- 21 ng at the highest dose examined (3.6 x 10(9) plaque-forming units). The injection of 200 micrograms of plasmid DNA (pRSVL) produced levels of luciferase comparable to 1.8 x 10(8) plaque-forming units of recombinant Ad5; however, when normalized to the number of genes injected, the adenovirus was 140,000 times more efficient than plasmid DNA. Histochemical analysis of beta-galactosidase activity produced by a second Ad5 vector demonstrated that nearly all (> 95%) of the stained cells were cardiomyocytes and that the percentage of cardiomyocytes infected by the virus could be quite high in microscopic regions adjacent to the needle track (up to 75% in fields of 60 to 70 cells); however, Ad5-infected cells were rarely observed farther than 5 mm from the injection site. Furthermore, the Ad5 vector induced pronounced leukocytic infiltration that was far in excess of that seen after injection of vehicle alone.
CONCLUSIONS: This study demonstrates for the first time that direct intramyocardial injection of replication-deficient adenovirus can program recombinant gene expression in the cardiomyocytes of a large animal species with relevance to human physiology. The efficiency of adenovirus-mediated gene transfer is far superior to that of plasmid DNA injection, and this method appears to be capable of producing more recombinant protein. However, the cell-mediated immune response to the Ad5 vector and the limited distribution of reporter gene expression suggest that less immunogenic recombinant vectors and more homogeneous administration methods will be required before Ad5 vectors can be successfully used for phenotypic modulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525108     DOI: 10.1161/01.cir.90.5.2414

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

Review 1.  The evolution of heart gene delivery vectors.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Dongsheng Duan
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 2.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

Review 3.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

Review 4.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells.

Authors:  Lara Pickel; Takaya Matsuzuka; Chiyo Doi; Rie Ayuzawa; Dharmendra Kumar Maurya; Sheng-Xue Xie; Cory Berkland; Masaaki Tamura
Journal:  Cancer Biol Ther       Date:  2009-12-22       Impact factor: 4.742

7.  Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo.

Authors:  J D White; D M Thesier; J B D Swain; M G Katz; C Tomasulo; A Henderson; L Wang; C Yarnall; A Fargnoli; M Sumaroka; A Isidro; M Petrov; D Holt; R Nolen-Walston; W J Koch; H H Stedman; J Rabinowitz; C R Bridges
Journal:  Gene Ther       Date:  2011-01-13       Impact factor: 5.250

Review 8.  Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Authors:  Shaina R Eckhouse; Jeffrey A Jones; Francis G Spinale
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

Review 9.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

10.  A simple technique to establish a long-term adenovirus mediated gene transfer to the heart of newborn mice.

Authors:  Marina Jerebtsova; Xuehai Ye; Patricio E Ray
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.